滋阴解毒方联合化疗治疗Ⅳ期Luminal B型乳腺癌的临床观察
发布时间：2018-10-12 17:30
【摘要】：目的:近年来乳腺癌的发病率逐年上升,对人类生活及健康产生了非常大的危害,已成为妇女健康的头号杀手。晚期乳腺癌的复发、转移是造成其预后不良及死亡的主要原因。目前包含化放疗及中医药治疗等方法的多学科综合治疗已在临床上被公认为是乳腺癌治疗的主要手段。本课题通过在临床观察,客观评价运用滋阴解毒方后对肝肾阴虚证型的Luminal B型乳腺癌患者的临床疗效,评估联合中医药在治疗过程中的有效性及安全性,从而为中医联合现代医学治疗乳腺癌提供临床参考。方法:本次课题研究对象为40例肝肾阴虚证型的Ⅳ期Luminal B型乳腺癌的患者,采取平行对照的设计办法分为治疗组以及对照组;对照组选用紫杉醇脂质体+卡培他滨的治疗方案,治疗组在对照组所选方案的基础上联合滋阴解毒方。治疗前后通过统计学软件分析评价体力状况、中医症状积分、肿瘤指标的变化情况;分析观察治疗后的近期疗效、化疗后出现的毒副反应的对比情况;分析探讨滋阴解毒方在临床治疗中所起到的作用。结果:在两组患者的KPS评分(体力状况)作用对比方面,经治疗后治疗组与对照组的KPS评分(体力状况)均较前改善,且两组之间的疗效对比差异具有统计学意义,治疗组对于患者体力的改善具有良好的效果。中医症状积分方面,结果显示两组别经治疗后,两组别患者中医临床症状均较前改善,治疗组治疗前后积分的变化较对照组明显(P0.05)。在近期疗效方面,对于肿瘤指标,两组经治疗后都有不同程度的下降,但差异没有统计学意义(P0.05)。总的控制率方面,治疗组(90%),对照组(80%);两组治疗后疾病控制率对比方面无统计学意义(P0.05)。在用药安全方面,两组的毒副反应主要体现在血液毒性、胃肠道反应以及肝肾损害方面;两组在化疗后的不良反应方面无统计学差异(P0.05),但在胃肠道反应方面,治疗组的例数少于对照组,且差异具有统计学意义(P0.05)。结论:滋阴解毒方联合紫杉醇脂质体+卡培他滨在提高患者的体力状况、改善患者的临床症状方面体现出一定的优势;虽在肿瘤标志物及总的疗效方面未见明显差异,但没有增加治疗后的不良反应,并在减轻化疗后的胃肠道反应方面表现出优势。体现了中西医结合治疗乳腺癌的可行性与一定的优越性。
[Abstract]:Objective: in recent years, the incidence of breast cancer has increased year by year, which has caused great harm to human life and health, and has become the number one killer of women's health. Recurrence and metastasis of advanced breast cancer are the main causes of poor prognosis and death. At present, multidisciplinary comprehensive therapy, including chemotherapeutic therapy and traditional Chinese medicine, has been recognized as the main method of breast cancer treatment. Through clinical observation, objective evaluation of the clinical efficacy of Ziyin jiedu prescription on Luminal B type breast cancer patients with liver and kidney yin deficiency syndrome, and to evaluate the efficacy and safety of combined Chinese medicine in the treatment process. So as to provide a clinical reference for the combination of TCM and modern medicine in the treatment of breast cancer. Methods: forty patients with stage 鈪，
本文编号：2266987
[Abstract]:Objective: in recent years, the incidence of breast cancer has increased year by year, which has caused great harm to human life and health, and has become the number one killer of women's health. Recurrence and metastasis of advanced breast cancer are the main causes of poor prognosis and death. At present, multidisciplinary comprehensive therapy, including chemotherapeutic therapy and traditional Chinese medicine, has been recognized as the main method of breast cancer treatment. Through clinical observation, objective evaluation of the clinical efficacy of Ziyin jiedu prescription on Luminal B type breast cancer patients with liver and kidney yin deficiency syndrome, and to evaluate the efficacy and safety of combined Chinese medicine in the treatment process. So as to provide a clinical reference for the combination of TCM and modern medicine in the treatment of breast cancer. Methods: forty patients with stage 鈪，
本文编号：2266987
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2266987.html
